Defendant
2 cases as defendant.
Eli Lilly and Company, commonly known as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company operates as a publicly traded entity on the New York Stock Exchange under the ticker LLY. As of 2025, Lilly employs approximately 50,000 people and reported revenues of around $65.18 billion. Its market capitalization was approximately $908.56 billion in May 2026, making it one of the most valuable pharmaceutical companies globally.
Lilly focuses on the discovery, development, manufacturing, and marketing of human healthcare products across key therapeutic areas. These include cardiometabolic health (diabetes, obesity, cardiovascular), oncology, immunology, and neuroscience. Major product lines feature treatments such as tirzepatide (Mounjaro and Zepbound) for type 2 diabetes and weight loss, abemaciclib (Verzenio) for breast cancers, and dulaglutide (Trulicity) for type 2 diabetes. The company also produces various insulin products, including Humulin and Humalog.
Eli Lilly & Co.'s patent litigation posture is defensive, consistent with an operating company protecting its product portfolio. The company has been named as a defendant in two tracked cases and has zero plaintiff cases. Both instances are before the Patent Trial and Appeal Board (PTAB), a venue where third parties can challenge the validity of existing patents.
The tracked cases, BPI Labs, LLC v. Eli Lilly & Co. and EmPower Clinic Services, L.L.C. v. Eli Lilly & Co., initiated in 2025, reflect challenges to Eli Lilly's patents at the PTAB. These actions indicate that the company is actively defending its intellectual property rights related to its pharmaceutical innovations.
An IPR petition filed by BPI Labs, LLC against Eli Lilly & Co. concerning US Patent 9474780 was discretionarily denied by the PTAB Director on December 11, 2025.
This IPR petition, filed by EmPower Clinic Services against Eli Lilly & Co. regarding US Patent 9474780, was denied institution by the PTAB for discretionary reasons in October 2025.